Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a clinical-stage biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Founded in 2014 and headquartered in Bedford, Massachusetts, the company pioneered the TANGO (Targeted Augmentation of Nuclear Gene Output) approach, which uses antisense oligonucleotides (ASOs) to selectively increase the productive splicing of pre-mRNA, thereby boosting the expression of proteins encoded by haploinsufficient genes. Stoke's lead program, zorevunersen (STK-001), targets Dravet syndrome, a severe and treatment-resistant genetic epilepsy caused by haploinsufficiency of the SCN1A gene. The company has also applied its platform to other neurological conditions including SYNGAP1-related intellectual disability. With a pipeline built on a foundational understanding of RNA biology, Stoke aims to address a broad range of genetic diseases where restoring even partial protein expression could meaningfully improve patient outcomes.